Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...

A new study by Liverpool John Moores University scientists suggests that women using Hormone Replacement Therapy (HRT) to ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's ...

GROUNDBREAKING research has shown that chronic intestinal infections caused by cytomegalovirus (HCMV) may play a role in a ...

Dementia is the loss of memory, language, problem-solving and other abilities that require thinking. It is often caused by ...

In July 2024, people living with early Alzheimer’s and organizations such as the Alzheimer’s Association celebrated FDA ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...